BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17972171)

  • 41. Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer.
    Karppinen SM; Heikkinen K; Rapakko K; Winqvist R
    J Med Genet; 2004 Sep; 41(9):e114. PubMed ID: 15342711
    [No Abstract]   [Full Text] [Related]  

  • 42. BARD1 Gene Polymorphisms Confer Nephroblastoma Susceptibility.
    Fu W; Zhu J; Xiong SW; Jia W; Zhao Z; Zhu SB; Hu JH; Wang FH; Xia H; He J; Liu GC
    EBioMedicine; 2017 Feb; 16():101-105. PubMed ID: 28161399
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer.
    Downs B; Kim YC; Xiao F; Snyder C; Chen P; Fleissner EA; Becirovic D; Wen H; Sherman S; Cowan KH; Lynch HT; Wang SM
    Breast Cancer Res Treat; 2015 May; 151(1):219-24. PubMed ID: 25833210
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Disease family history and modification of breast cancer risk in common BRCA2 variants.
    Seymour IJ; Casadei S; Zampiga V; Rosato S; Danesi R; Falcini F; Strada M; Morini N; Naldoni C; Paradiso A; Tommasi S; Schittulli F; Amadori D; Calistri D
    Oncol Rep; 2008 Mar; 19(3):783-6. PubMed ID: 18288416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.
    Wu JY; Vlastos AT; Pelte MF; Caligo MA; Bianco A; Krause KH; Laurent GJ; Irminger-Finger I
    Int J Cancer; 2006 Mar; 118(5):1215-26. PubMed ID: 16152612
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BARD1 splice variants display mislocalization in breast cancer cells and can alter the apoptotic response to cisplatin.
    Marzec KA; Martino-Echarri E; Irminger-Finger I; Henderson BR
    Cancer Lett; 2016 Oct; 381(1):149-55. PubMed ID: 27477900
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors.
    Arnold JM; Choong DY; Thompson ER; ; Waddell N; Lindeman GJ; Visvader JE; Campbell IG; Chenevix-Trench G
    Breast Cancer Res Treat; 2010 Jan; 119(2):491-6. PubMed ID: 19189213
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mutations in exon region of BRCA1-related RING domain 1 gene and risk of breast cancer.
    Wu J; Aini A; Ma B
    Mol Genet Genomic Med; 2022 Mar; 10(3):e1847. PubMed ID: 35084806
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.
    Ticha I; Kleibl Z; Stribrna J; Kotlas J; Zimovjanova M; Mateju M; Zikan M; Pohlreich P
    Breast Cancer Res Treat; 2010 Nov; 124(2):337-47. PubMed ID: 20135348
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
    Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
    Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.
    Guénard F; Pedneault CS; Ouellette G; Labrie Y; Simard J; ; Durocher F
    Genet Test Mol Biomarkers; 2010 Aug; 14(4):515-26. PubMed ID: 20722467
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility.
    Capasso M; Diskin SJ; Totaro F; Longo L; De Mariano M; Russo R; Cimmino F; Hakonarson H; Tonini GP; Devoto M; Maris JM; Iolascon A
    Carcinogenesis; 2013 Mar; 34(3):605-11. PubMed ID: 23222812
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mutations and polymorphic BRCA variants transmission in breast cancer familial members.
    Pilato B; Martinucci M; Danza K; Pinto R; Petriella D; Lacalamita R; Bruno M; Lambo R; D'Amico C; Paradiso A; Tommasi S
    Breast Cancer Res Treat; 2011 Feb; 125(3):651-7. PubMed ID: 20352487
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TGFBR1(*)6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancer.
    Song B; Margolin S; Skoglund J; Zhou X; Rantala J; Picelli S; Werelius B; Lindblom A
    Br J Cancer; 2007 Oct; 97(8):1175-9. PubMed ID: 17848956
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bioinformatics Analysis of Expression and Alterations of BARD1 in Breast Cancer.
    Chen YZ; Zuo D; Ren HL; Fan SJ; Ying G
    Technol Cancer Res Treat; 2019; 18():1533033819892260. PubMed ID: 31808361
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor.
    Cimmino F; Avitabile M; Diskin SJ; Vaksman Z; Pignataro P; Formicola D; Cardinale A; Testori A; Koster J; de Torres C; Devoto M; Maris JM; Iolascon A; Capasso M
    Int J Cancer; 2018 Dec; 143(11):2828-2837. PubMed ID: 30132831
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival.
    Kim J; Vaksman Z; Egolf LE; Kaufman R; Evans JP; Conkrite KL; Danesh A; Lopez G; Randall MP; Dent MH; Farra LM; Menghani NL; Dymek M; Desai H; Hausler R; Hicks B; Auvil JG; Gerhard DS; Hakonarson H; Maxwell KN; Cole KA; Pugh TJ; Bosse KR; Khan J; Wei JS; Maris JM; Stewart DR; Diskin SJ
    J Natl Cancer Inst; 2024 Jan; 116(1):149-159. PubMed ID: 37688579
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Association between GWAS-identified BARD1 Gene SNPs and Neuroblastoma Susceptibility in a Southern Chinese Population.
    Zhang R; Zou Y; Zhu J; Zeng X; Yang T; Wang F; He J; Xia H
    Int J Med Sci; 2016; 13(2):133-8. PubMed ID: 26941572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.